المصدر: ECHELON-2 Study Group 2019 , ' Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2) : a global, double-blind, randomised, phase 3 trial ' , Lancet (London, England) , vol. 393 , no. 10168 , pp. 229-240 . https://doi.org/10.1016/S0140-6736Test(18)32984-2

مصطلحات موضوعية: Adult, Aged, Antineoplastic Agents/administration & dosage, Antineoplastic Combined Chemotherapy Protocols/therapeutic use, Cyclophosphamide/administration & dosage, Disease-Free Survival, Double-Blind Method, Doxorubicin/administration & dosage, Female, Humans, Immunoconjugates/administration & dosage, Immunologic Factors/administration & dosage, Intention to Treat Analysis, Lymphoma, Large-Cell, Anaplastic/drug therapy, Male, Middle Aged, Prednisone/administration & dosage, Vincristine/administration & dosage, ResearchInstitutes_Networks_Beacons/lydia_becker_institute_of_immunology_and_inflammation, name=Lydia Becker Institute, ResearchInstitutes_Networks_Beacons/mcrc, name=Manchester Cancer Research Centre

وصف الملف: application/pdf

العلاقة: https://research.manchester.ac.uk/en/publications/4ce422c9-a1da-4c56-83d6-b88bf66adb9eTest

الإتاحة: https://doi.org/10.1016/S0140-6736Test(18)32984-2
https://research.manchester.ac.uk/en/publications/4ce422c9-a1da-4c56-83d6-b88bf66adb9eTest
https://pure.manchester.ac.uk/ws/files/133770819/THELANCETPUBLICHEALTH_S_19_00758_2_.pdfTest

المؤلفون: Horwitz, Steven, O'Connor, Owen A, Pro, Barbara, Illidge, Tim, Fanale, Michelle, Advani, Ranjana, Bartlett, Nancy L, Christensen, Jacob Haaber, Morschhauser, Franck, Domingo-Domenech, Eva, Rossi, Giuseppe, Kim, Won Seog, Feldman, Tatyana, Lennard, Anne, Belada, David, Illés, Árpád, Tobinai, Kensei, Tsukasaki, Kunihiro, Yeh, Su-Peng, Shustov, Andrei, Hüttmann, Andreas, Savage, Kerry J, Yuen, Sam, Iyer, Swaminathan, Zinzani, Pier Luigi, Hua, Zhaowei, Little, Meredith, Rao, Shangbang, Woolery, Joseph, Manley, Thomas, Trümper, Lorenz

المصدر: Horwitz , S , O'Connor , O A , Pro , B , Illidge , T , Fanale , M , Advani , R , Bartlett , N L , Christensen , J H , Morschhauser , F , Domingo-Domenech , E , Rossi , G , Kim , W S , Feldman , T , Lennard , A , Belada , D , Illés , Á , Tobinai , K , Tsukasaki , K , Yeh , S-P , Shustov , A , Hüttmann , A , Savage , K J , Yuen , S , Iyer , ....

مصطلحات موضوعية: Adult, Aged, Antineoplastic Agents/administration & dosage, Antineoplastic Combined Chemotherapy Protocols/therapeutic use, Cyclophosphamide/administration & dosage, Disease-Free Survival, Double-Blind Method, Doxorubicin/administration & dosage, Female, Humans, Immunoconjugates/administration & dosage, Immunologic Factors/administration & dosage, Intention to Treat Analysis, Lymphoma, Large-Cell, Anaplastic/drug therapy, Male, Middle Aged, Prednisone/administration & dosage, Vincristine/administration & dosage

العلاقة: https://portal.findresearcher.sdu.dk/da/publications/01911b31-02ec-4e43-85dc-e2e7c9245589Test

الإتاحة: https://doi.org/10.1016/S0140-6736Test(18)32984-2
https://portal.findresearcher.sdu.dk/da/publications/01911b31-02ec-4e43-85dc-e2e7c9245589Test
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6436818/pdf/nihms-1515984.pdfTest

المؤلفون: Rossin, Raffaella, Versteegen, Ron M., Wu, Jeremy, Khasanov, Alisher, Wessels, Hans J., Steenbergen, Erik J., ten Hoeve, Wolter, Janssen, Henk M., van Onzen, Arthur H.A.M., Hudson, Peter J., Robillard, Marc S.

المصدر: Rossin , R , Versteegen , R M , Wu , J , Khasanov , A , Wessels , H J , Steenbergen , E J , ten Hoeve , W , Janssen , H M , van Onzen , A H A M , Hudson , P J & Robillard , M S 2018 , ' Chemically triggered drug release from an antibody-drug conjugate leads to potent antitumour activity in mice ' , Nature Communications , vol. 9 , no. 1 , 1484 . https://doi.org/10.1038/s41467-018-03880-yTest

مصطلحات موضوعية: Animals, Antigens, Neoplasm/chemistry, Antineoplastic Agents/administration & dosage, Brentuximab Vedotin, Cell Line, Tumor, Drug Liberation, Female, Glycoproteins/antagonists & inhibitors, HT29 Cells, Humans, Immunoconjugates/administration & dosage, Mice, Inbred BALB C, Nude, Neoplasms, Experimental/drug therapy, Xenograft Model Antitumor Assays, /dk/atira/pure/sustainabledevelopmentgoals/good_health_and_well_being, name=SDG 3 - Good Health and Well-being

وصف الملف: application/pdf

العلاقة: https://research.tue.nl/en/publications/e37d6b6f-65df-4929-8563-a399982085efTest

الإتاحة: https://doi.org/10.1038/s41467-018-03880-yTest
https://research.tue.nl/en/publications/e37d6b6f-65df-4929-8563-a399982085efTest
https://pure.tue.nl/ws/files/101888135/s41467_018_03880_y.pdfTest
http://www.scopus.com/inward/record.url?scp=85046624853&partnerID=8YFLogxKTest

المؤلفون: Rossin, Raffaella, Versteegen, Ron M., Wu, Jeremy, Khasanov, Alisher, Wessels, Hans J., Steenbergen, Erik J., ten Hoeve, Wolter, Janssen, Henk M., van Onzen, Arthur H.A.M., Hudson, Peter J., Robillard, Marc S.

المصدر: Rossin , R , Versteegen , R M , Wu , J , Khasanov , A , Wessels , H J , Steenbergen , E J , ten Hoeve , W , Janssen , H M , van Onzen , A H A M , Hudson , P J & Robillard , M S 2018 , ' Chemically triggered drug release from an antibody-drug conjugate leads to potent antitumour activity in mice ' , Nature Communications , vol. 9 , no. 1 , 1484 . https://doi.org/10.1038/s41467-018-03880-yTest

مصطلحات موضوعية: Animals, Antigens, Neoplasm/chemistry, Antineoplastic Agents/administration & dosage, Brentuximab Vedotin, Cell Line, Tumor, Drug Liberation, Female, Glycoproteins/antagonists & inhibitors, HT29 Cells, Humans, Immunoconjugates/administration & dosage, Mice, Inbred BALB C, Nude, Neoplasms, Experimental/drug therapy, Xenograft Model Antitumor Assays, /dk/atira/pure/sustainabledevelopmentgoals/good_health_and_well_being, name=SDG 3 - Good Health and Well-being

وصف الملف: application/pdf

العلاقة: https://research.tue.nl/en/publications/e37d6b6f-65df-4929-8563-a399982085efTest

الإتاحة: https://doi.org/10.1038/s41467-018-03880-yTest
https://research.tue.nl/en/publications/e37d6b6f-65df-4929-8563-a399982085efTest
https://pure.tue.nl/ws/files/101888135/s41467_018_03880_y.pdfTest
http://www.scopus.com/inward/record.url?scp=85046624853&partnerID=8YFLogxKTest

المؤلفون: Caimi, Paolo F, Ai, Weiyun, Alderuccio, Juan Pablo, Ardeshna, Kirit M, Hamadani, Mehdi, Hess, Brian, Kahl, Brad S, Radford, John, Solh, Melhem, Stathis, Anastasios, Zinzani, Pier Luigi, Havenith, Karin, Feingold, Jay, He, Shui, Qin, Yajuan, Ungar, David, Zhang, Xiaoyan, Carlo-Stella, Carmelo

المصدر: Caimi , P F , Ai , W , Alderuccio , J P , Ardeshna , K M , Hamadani , M , Hess , B , Kahl , B S , Radford , J , Solh , M , Stathis , A , Zinzani , P L , Havenith , K , Feingold , J , He , S , Qin , Y , Ungar , D , Zhang , X & Carlo-Stella , C 2021 , ' Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2) : a multicentre, open-label, single-arm, phase 2 trial ' ....

مصطلحات موضوعية: Adolescent, Adult, Aged, Antibodies, Monoclonal, Humanized/administration & dosage, Antigens, CD19/drug effects, Benzodiazepines/administration & dosage, Drug-Related Side Effects and Adverse Reactions/classification, Female, Humans, Immunoconjugates/administration & dosage, Italy/epidemiology, Lymphoma, Large B-Cell, Diffuse/drug therapy, Male, Middle Aged, Neoplasm Recurrence, Local/drug therapy, Recurrence, Switzerland/epidemiology, Young Adult, ResearchInstitutes_Networks_Beacons/mcrc, Manchester Cancer Research Centre

الإتاحة: https://doi.org/10.1016/S1470-2045Test(21)00139-X
https://research.manchester.ac.uk/en/publications/f1185252-6a3a-4377-a63f-f9054cdc1701Test

المؤلفون: Ton, N. C., Parker, G. J M, Jackson, A., Mullamitha, S., Buonaccorsi, G. A., Roberts, C., Watson, Y., Davies, K., Cheung, S., Hope, L., Power, F., Lawrance, J., Valle, J., Saunders, M., Felix, R., Soranson, J. A., Rolfe, L., Zinkewich-Peotti, K., Jayson, Gordon C.

المصدر: Ton , N C , Parker , G J M , Jackson , A , Mullamitha , S , Buonaccorsi , G A , Roberts , C , Watson , Y , Davies , K , Cheung , S , Hope , L , Power , F , Lawrance , J , Valle , J , Saunders , M , Felix , R , Soranson , J A , Rolfe , L , Zinkewich-Peotti , K & Jayson , G C 2007 , ' Phase I evaluation of CDP791, a PEGylated Di-Fab′ conjugate that binds vascular endothelial growth factor ....

مصطلحات موضوعية: Adolescent, Adult, Aged, 80 and over, Angiogenesis Inhibitors/*administration & dosage/adverse, effects/pharmacokinetics, Cohort Studies, Dose-Response Relationship, Drug, Drug Administration Schedule, Female, Humans, Immunoconjugates/*administration & dosage/adverse effects/pharmacokinetics, Immunoglobulin Fab Fragments/*administration & dosage/adverse, effects/metabolism, Magnetic Resonance Imaging, Male, Middle Aged, Neoplasms/blood supply/*drug therapy, Polyethylene Glycols/*administration & dosage/adverse, Vascular Endothelial Growth Factor Receptor-2/*antagonists &, inhibitors/blood

الإتاحة: https://doi.org/10.1158/1078-0432.CCR-07-1550Test
https://research.manchester.ac.uk/en/publications/adc88d83-1c4a-433d-9691-e35bc61bfcd5Test
http://clincancerres.aacrjournals.org/cgi/reprint/13/23/7113Test
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=18056191Test